Back to Registry

Delta Sleep-Inducing Peptide

Also known as: DSIP, Emideltide, DSIP Nonapeptide, Delta Sleep Peptide

FDA Banned (Category B)

Molecular Formula

C35 H48 N10 O15

Molecular Weight

848.83 Da

Half-Life

~15 minutes (in vitro); 2–4 minutes (in vivo plasma clearance)

Sequence

WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)

Clinical Applications & Evidence

Mechanism of Action

Multi-pathway neuromodulation: Potentiates GABAergic inhibitory currents and antagonizes NMDA-activated glutamatergic excitotoxicity. Modulates monoamine turnover (serotonin/dopamine). Regulates the HPA axis by reducing basal corticotropin (ACTH) and optimizing the nocturnal rise of N-acetyltransferase. Enhances mitochondrial respiration and upregulates antioxidant enzymes (Superoxide Dismutase, Glutamate Peroxidase).

Investigated Uses

  • Sleep disorders and intractable insomnia
  • Opiate and alcohol withdrawal syndromes
  • Chronic pain syndromes (migraines, tinnitus)
  • Ischemic stroke recovery and motor function restoration
  • Seizure management and anticonvulsant potentiation
  • Tissue repair via circadian/mitochondrial regulation
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

FDA Banned (Category B)

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

HeadacheNauseaVertigoPotential immunogenicity / systemic allergic response

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active malignancies / personal history of cancer

Drug Interactions

  • Peptidase inhibitors (e.g., Captopril)
  • Anticonvulsants (potentiates Valproate)
  • CNS depressants
  • Exogenous opioids and alcohol

Citations & Clinical Trials

PubMed Acute and delayed effects of DSIP on human sleep behavior PubMed Some pharmacological effects of DSIP FDA Certain Bulk Drug Substances Used in Compounding May Present Significant Safety Risks PubMed Development of an EIA for DSIP and determination of metabolic clearance rate